DIRS.INFO The most relevant business & tech news

☆ Beyond Novo: Fund manager likes this under-the-radar pharma stock with a weight loss drug in the works
▼ + stars: | 2024-10-04 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

"Maybe that weight loss product (by United Laboratories) works, maybe it doesn't. United Laboratories' price-to-earnings of 5.8 times is a fraction of the 34.3 times that Novo Nordisk is trading at, Peche added. [United Laboratories] is making smooth progress in R & D and targets to launch Liraglutide in 2024. Their comments follow United Laboratories' "faster than expected earnings" growth in the first half of the year. Analysts' average price target on United Laboratories is 12.95 Hong Kong dollars, giving it 28.2% potential upside.

Persons: Sean Peche, it's, Peche, there's, that's, Eli Lilly, Amgen, Carol Dou, Sunny Chen, UOB Kay Hian, bode Organizations: Novo Nordisk, Ranmore Fund Management, United Laboratories, Pfizer, AstraZeneca, Global Equity Fund, Hong, Hong Kong bourse, HK Locations: Hong Kong, Novo, Europe, U.S

☆ These are the most important stocks in the U.S., according to Bank of America
▼ + stars: | 2024-10-04 | by ( Pia Singh | In | ) www.cnbc.com time to read: +3 min

There are several key stocks in the U.S. investors need to be mindful of when navigating the current market environment, according to Bank of America. To capture the momentum from this rally, Bank of America screened for the most important stocks in each region of the world — including the U.S. — that have the potential to have the largest impact on portfolio performance, positive or negative. Bank of America found these stocks to be among the most important in the U.S.: Chipmaker Nvidia and oil and gas giant Exxon Mobil ranked fairly high on the firm's steady compounders list within the screen. Meta's shares are up nearly 64% year to date. Other stocks considered the most important names in the U.S. include rideshare company Uber and pharma name Eli Lilly .

Persons: Nigel Tupper, Vivek Arya's, Metaverse, Justin Post, Eli Lilly Organizations: Bank of America, Investment, U.S, Nvidia, Exxon Mobil, Exxon, Meta, Bank of America's, Uber Locations: U.S, Lebanon, Thursday's

☆ How the port strike could actually boost Costco sales
▼ + stars: | 2024-10-03 | by ( Paulina Likos | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Club stock Nvidia jumped more than 3% — bucking the pressure on Big Tech. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jensen Huang, Eli Lilly, Lilly, Oppenheimer, Jim Cramer's, Jim Organizations: CNBC, Wall, Nvidia, Big Tech, Blackwell, Broadcom, Devices, Food and Drug Administration, Costco, AMD Locations: New Jersey

☆ Calls of the Day: Tesla, Eli Lilly and Bank Of America
▼ + stars: | 2024-10-03 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCalls of the Day: Tesla, Eli Lilly and Bank Of AmericaThe Investment Committee debate the latest Calls of The Day.

Persons: Tesla, Eli Lilly Organizations: Bank, America, Investment

☆ Stocks making the biggest moves midday: Hims & Hers Health, Joby Aviation, Levi Strauss and more
▼ + stars: | 2024-10-03 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

EVgo — Shares soared 55% after the electric vehicle charger company received a $1.05 billion conditional loan from the Department of Energy. Hims & Her Health had previously developed compound versions of the drugs to take advantage of the shortage. Joby Aviation – Shares dropped more than 7%, paring back gains made in the previous session. Palantir recently announced that it's partnering with Edgescale AI to deliver Live Edge, a platform that will utilize artificial intelligence for manufacturing, utilities and other areas. Investors see both Vistra and Constellation as becoming key supporters of data center growth for developing tech companies' artificial intelligence technologies.

Persons: Bill Peterson, Eli Lilly, paring, Joby, Levi Strauss, Levi, Jensen Huang, CNBC's, Blackwell, Henning Cosman, Palantir, Sundar Pichai, Yun Li, Lisa Kailai Han, Hakyung Kim Organizations: Department of Energy, JPMorgan, U.S . Food, Drug Administration, Toyota, Dockers, Wolfspeed, Mizuho, Nvidia, Barclays, Constellation Energy, Nikkei, Investors Locations: U.S, China

☆ 10 things to watch in the market Thursday, including great news from Nvidia's CEO
▼ + stars: | 2024-10-03 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

My top 10 things to watch Thursday, Oct. 3 Today's newsletter was written by the Investing Club's director of portfolio analysis, Jeff Marks. But the analysts said they would be buyers of the Club stock on weakness in 2025. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. My top 10 things to watch Thursday, Oct. 3Today's newsletter was written by the Investing Club's director of portfolio analysis, Jeff Marks. But the analysts said they would be buyers of the Club stock on weakness in 2025.

Persons: Jeff Marks, Stocks, Dow, Beer, Jensen Huang, Blackwell, Eli Lilly, Morgan Stanley, Oppenheimer, Levi Strauss, Levi, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Constellation Brands, Modelo, Corona, Constellation, Nvidia, CNBC, Club, Bank of America, Devices, Amazon, Deutsche Bank, Costco, Dockers, Barclays, PepsiCo, Jim Cramer's Charitable Locations: Northern New Jersey, Europe, Americas

☆ Stocks making the biggest moves premarket: Nvidia, Levi Strauss, EVgo and more
▼ + stars: | 2024-10-03 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +2 min

EVgo — Shares advanced more than 9% after JPMorgan upgraded the electric vehicle charging company to overweight . Levi Strauss — Shares plunged 12% after the denim maker trimmed its full-year revenue guidance and delivered fiscal third-quarter revenue that missed analysts' expectations. Constellation Brands — The beverage company rose slightly on the back of better-than-expected fiscal second-quarter earnings. Revenue of $2.92 billion, however, marginally missed expectations. Stellantis — The automaker was down more than 3% in the premarket after a Barclays downgrade to equal weight from overweight.

Persons: Mizuho, Jensen Huang, CNBC's, Blackwell, Eli Lilly, Bill Peterson, Levi Strauss —, Stellantis, Henning Cosman, — CNBC's Brian Evans, Lisa Han, Jesse Pound, Sean Conlon Organizations: Mizuho, Nvidia –, U.S . Food, Drug Administration, JPMorgan, Dockers, Constellation Brands, Barclays Locations: U.S

☆ Eli Lilly CEO: We have 11 pipeline projects in obesity
▼ + stars: | 2024-10-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO: We have 11 pipeline projects in obesityCNBC's Angelica Peebles joins 'Squawk on the Street' to report on Eli Lilly's new investment in a new $4.5 billion research and development center.

Persons: Eli Lilly, CNBC's Angelica Peebles, Eli Lilly's

☆ Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
▼ + stars: | 2024-10-02 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it to propel the rest of its pipeline. Lilly says the facility will be the first of its kind to combine research and production in a single location. It will be near a $9 billion manufacturing complex Lilly is building in Lebanon, Indiana, to produce pharmaceutical ingredients like tirzepatide, the active ingredient in Mounjaro and Zepbound.

Persons: Eli Lilly, Mounjaro, Lilly, David Ricks, –, Dan Skovronsky Organizations: Lilly, Foundry, Indianapolis, Novo Nordisk's Ozempic Locations: Indianapolis, Lebanon , Indiana, tirzepatide

☆ Here are JPMorgan's top stock picks heading into October
▼ + stars: | 2024-10-02 | by ( Sean Conlon | ) www.cnbc.com time to read: +4 min

For October, the additions include Best Buy and Carmax , while Wayfair , CarGurus and First Citizens BancShares are among those removed. The bank cited positive existing home sales, and an expansion in AI adoption, believing Best Buy will see continued growth in average selling prices . Analyst Christopher Horvers says Best Buy will increase its profitability over time, noting an uptick in operating margins to 5% from last year's 4.1%. He has an overweight rating on the stock, and his price target of $111 implies more than 9% upside from Tuesday's close. The bank's price target for Schwab implied about 22% upside and for Ulta Beauty about 18% potential appreciation, based on Tuesday's close.

Persons: JPMorgan's, Christopher Horvers, BBY, Eli Lilly, Lilly, Charles Schwab, Schwab Organizations: JPMorgan, Nasdaq, Dow Jones, Wall, AT, TPG Locations: Israel, Richland , Minnesota, Dallas, DirectTV, Lilly, Ireland

☆ 3-Stock Lunch: Nike, Humana & Eli Lilly
▼ + stars: | 2024-10-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email3-Stock Lunch: Nike, Humana & Eli LillyAnthony Forcione, Rockland Trust VP, joins 'Power Lunch' to discuss stock plays for three stocks.

Persons: Eli Lilly Anthony Forcione Organizations: Nike, Humana, Rockland Trust

☆ Port strike fallout: Blockbuster weight-loss drug supply from Wegovy to Ozempic, Mounjaro, Zepbound caught up in East Coast trade shutdown
▼ + stars: | 2024-10-01 | by ( Lori Ann Larocco | ) www.cnbc.com time to read: +3 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTAn Eli Lilly & Co. Zepbound injection pen, March 28, 2024. Bills of lading, the digital receipts of freight containers, show that the delivery mechanisms for insulin and weight-loss drugs rely on East Coast ports for incoming trade. "Novo Nordisk and Eli Lilly are both heavily reliant on the Port of Norfolk," said William George, director of Research at ImportGenius, which tracks the customs data. Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. Bloomberg | Bloomberg | Getty ImagesAn Eli Lilly spokesperson said it does not discuss the details of its external supplier relationships.

Persons: Eli Lilly, Eli Lilly — Ozempic, William George, George, Dennis Monts Organizations: Bloomberg, Getty, Novo Nordisk, ILA, Nordisk, Research, U.S . Senate, CNBC, Nuco Logistics Locations: New England, Texas, U.S, lading, East Coast, Port of Norfolk, ImportGenius, Norfolk, airfreight, Hillerod, Denmark, Monts

☆ GE Healthcare has been an under-the-radar winner — and a new catalyst just arrived
▼ + stars: | 2024-09-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

Wall Street currently sees GE Healthcare earning $6.72 per share in 2028, according to FactSet, up from $4.25 projected this year. GE Healthcare has been a stock we've been battling since its steep slide during the second quarter. That dynamic — coupled with the positive China stimulus announcements in recent days — turned GE Healthcare into one of our top-performing stocks in the third quarter . A PET scan using Flyrcado has better diagnostic efficacy than SPECT scans, according to GE Healthcare. GE Healthcare may also see a recovery in its China business due to the roll out of medical-focused stimulus spending .

Persons: Wells, Flyrcado —, Wells Fargo, Flyrcado, FactSet, Jim Cramer, —, Jim, Leqembi, Eli Lilly, Stifel, Jim Cramer's, Yi Haifei Organizations: GE Healthcare, GE, Food and Drug Administration, Wall, FDA, Federal, Club, CDC, Management, CNBC, Fair for Trade, Services, China National Convention Center, China News Service, Getty Locations: China, U.S, Beijing

☆ The one sector of the stock market that is cheap with upside today
▼ + stars: | 2024-09-29 | by ( Karen Firestone | ) www.cnbc.com time to read: +5 min

The table and chart below illustrate some characteristics of the biopharma stocks. The average price/earnings multiple for the group, using 2025 estimates, is 12.7 times versus 20.6 times for the S & P 500. A major knock on the biopharma group is the limited productivity from their extremely expensive research efforts, other than obesity drugs, over the past twenty-five years. The technology using AI might not be ready yet, particularly related to the complex biology of the human body. Complex programs exist already, such as AlphaFold, which predicts the structure of three-dimensional compounds using data on protein sequences.

Persons: Bristol Myers, Amgen, Eli Lilly, Lilly, Johnson Organizations: CNBC, Merck, Pfizer, Novo Nordisk, JPMorgan Locations: Bristol

☆ Insider Today: Austin's genius housing fix
▼ + stars: | 2024-09-28 | by ( Joi-Marie Mckenzie | ) www.businessinsider.com time to read: +7 min

This week's dispatchThe high cost of weight-loss drugsiStock; Rebecca Zisser/BIWhy are two popular weight-loss drugs — Wegovy and diabetes medication Ozempic — so expensive in the US? Patients also bargain-hunt for cheaper weight-loss drugs online, or try to use manufacturer-issued coupons. See the full listiStock; Rebecca Zisser/BIDeals we loveCalling all Madewell shoppers: The bi-annual Madewell Insiders sale is here with 25% off almost everything full-price and an additional 40% off sale. The bi-annual Madewell Insiders sale is here with 25% off almost everything full-price and an additional 40% off sale. The Insider Today team: Dan DeFrancesco, deputy editor and anchor, in New York City.

Persons: —, you've, Shailene Woodley, George Clooney, Rebecca Zisser, Ozempic, Lars Fruergaard Jorgensen, Sen, Bernie Sanders, it's, Gabby Landsverk, Ro, Henry Meds, Eli Lilly, Stefania Pelfini, Jenny Chang, Rodriguez, BI Marie, Mangin, Yellowstone Joey Hadden, Jackson, Wyoming's, Natalie Ammari, Zers, Austin, Tyler Le, Dan DeFrancesco, Jordan Parker Erb, Lisa Ryan, Amanda Yen, Grace Lett Organizations: Business, Service, Novo Nordisk, Federal Trade Commission, FDA, copycats, BI, Yellowstone, Austin, Lone Star, Disney, Pixar, British, Netflix, Insiders Locations: Washington ,, Germany, New York City, New York, Chicago

☆ Move aside, AI: None of our top 5 stocks in the third quarter are in tech
▼ + stars: | 2024-09-27 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

The best-performing Club stocks during the topsy-turvy third quarter are all outside the "Magnificent Seven" and AI-winner complexes. Starbucks: 25.2% New CEO Brian Niccol is the reason why Starbucks' stock is on the list. Best Buy: 18.6% The electronics retailer is another rate-cut winner: More people moving means more purchases of appliances and TVs. In fact, the reasons to own Best Buy are underappreciated by investors, JPMorgan analysts said in a note to clients Friday. Like Stanley Black & Decker and Best Buy, Home Depot is a beneficiary of increased housing sector activity.

Persons: —, Stanley Black, Decker, Brian Niccol, Eli Lilly, Lilly, there's, Jim Cramer's, Jim Cramer, Jim, Donald Allan , Jr, Chris Taylor Organizations: Reserve, Starbucks, Deutsche Bank, GE Healthcare, Novo Nordisk, Abbott Laboratories, Abbott Labs, GE, JPMorgan, CNBC, The New York Stock Exchange, NYSE Global Locations: U.S, China

☆ How we're thinking about 7 portfolio stocks with ties to OpenAI after its latest shakeup
▼ + stars: | 2024-09-26 | by ( Morgan Chittum | ) www.cnbc.com time to read: +11 min

We're taking a keen interest because several stocks in the Club portfolio have ties to the startup behind ChatGPT. Co-founder Ilya Sutskever, who had been chief scientist, also left earlier this year and launched a new AI startup. Microsoft Microsoft got the first-mover advantage among big tech firms because of its early investment in OpenAI. As of now, we still haven't heard much about Lilly's exact plan to utilize OpenAI's technology. OpenAI CEO Sam Altman speaks during the Microsoft Build conference at Microsoft headquarters in Redmond, Washington, on May 21, 2024.

Persons: OpenAI, Sam Altman's, There's, Mira Murati, she's, Bob McGrew, Barret Zoph, Altman, Ilya Sutskever, it's, here's, ChatGPT, Jim Cramer, Jim, That's, —, OpenAI's, Jensen Huang, Nikesh Arora, Morgan Stanley Morgan Stanley, Morgan, Eli Lilly Eli Lilly, Eli Lilly's, Einstein, Marc Benioff, Jim Cramer's, Sam Altman, Jason Redmond Organizations: Club, Microsoft, Nvidia, Reuters, CNBC, Apple Intelligence, Apple, Bloomberg News, Street, Microsoft Microsoft, Blackwell, Palo, Palo Alto Networks, Employees, OpenAI, Barclays, Jim Cramer's Charitable, AFP, Getty Locations: OpenAI, Redmond, Washington, Palo Alto, Redmond , Washington

☆ Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
▼ + stars: | 2024-09-26 | by ( ) www.businessinsider.com time to read: +7 min

A woman who had life-changing results on a popular weight loss drug struggled to afford it for years. AdvertisementTara Rothenhoefer, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication. While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality. The grey market of weight-loss drugs is vast and complicated. In August, Eli Lilly halved the price of its weight-loss drug Zepbound through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.

Persons: —, Tara Rothenhoefer, Rothenhoefer, Eli Lilly, She's Organizations: Service, Novo Nordisk's, Research, FDA, Pharmaceutical Locations: Florida

☆ Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
▼ + stars: | 2024-09-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Novo Nordisk 's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study released Wednesday. The active ingredient in Ozempic, semaglutide, was associated with a "significantly lower" opioid overdose risk than other diabetes medications in people diagnosed with both Type 2 diabetes and opioid use disorder, said the paper published in JAMA Network Open. Around 3,000 people were prescribed semaglutide injections, while the remaining patients received treatments that ranged from insulins to older GLP-1s for diabetes. That reflects a 58% lower risk of opioid overdose in patients who took semaglutide, Xu said.

Persons: Dr, Rong Xu, Eli Lilly, Lilly's, Xu Organizations: Novo Nordisk, JAMA, Case Western Reserve University, Centers for Disease Control, National Center for Drug, U.S, National Institutes of Health, Novo Nordisk's Victoza Locations: London, Britain, Novo

☆ Is Ozempic to blame for the slowdown in salty snack sales? Here’s the verdict
▼ + stars: | 2024-09-24 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Sluggish salty snack sales have prompted questions about whether Ozempic and obesity treatments like Wegovy and Zepbound ae to blame. GLP-1 drugs have been cheered as an effective method to help patients with diabetes and obesity to manage their blood sugar levels, hunger and weight. Lieberman found that the temporary price reduction at Wal-Mart stores drove an increase in both the product's volume and sales, leading to the conclusion that snack sales were hurt by price pressures for consumers. "All said, the data suggests to us that the primary challenge facing the salty snack category is affordability and arguably not GLP-1s and evolving health & wellness trends as some people might opine," she wrote in the report. "The salty snack category raises prices faster than the rest of the grocery store, so we probably have more work to do to right-size the prices," he told CNBC in an interview.

Persons: Morgan Stanley, Campbell, Lauren Lieberman, Pepsi's, Lieberman, Cowen, Robert Moskow, Moskow, It's, TD Cowen, Nordisk's Wegovy, Eli Lilly's Zepbound, Dara Mohsenian, Mohsenian, There's Organizations: Pepsi, UTZ Brands, Barclays, Mart, CNBC, Nielsen Locations: confections, Nordisk's

☆ 10 things to watch in the stock market Tuesday, including long-awaited China stimulus
▼ + stars: | 2024-09-24 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

China related stocks were on the move Tuesday after the People's Bank of China said it will cut interest rates. What the Jefferies downgrade misses is the market is giving Starbucks a pass as Niccol builds his team and makes changes. Truist downgraded Club holding Costco to a hold rating ahead of earnings, which are out after Thursday's close. The analysts still have a hold-equivalent rating on Club holding Home Depot but boosted their price target to $400 per share. China related stocks were on the move Tuesday after the People's Bank of China said it will cut interest rates.

Persons: Brian Niccol, Chipotle, Jefferies, Truist, Salesforce, Piper Sandler, Oppenheimer, Regeneron, Eli Lilly, Pinterest, —, Jeff Marks, Jim Cramer's, Jim Cramer, Jim Organizations: People's Bank of, Starbucks, Jefferies, Costco, Walmart, Analysts, Barclays, Constellation Brands, Oppenheimer, Justice Department, Visa, Bloomberg, Jim Cramer's Charitable, CNBC Locations: China, People's Bank of China, Japan

☆ CNBC Pro Talks: After the Fed cuts rates, one fund manager will reveal where to invest right now
▼ + stars: | 2024-09-24 | by ( Cnbc.Com Staff | ) www.cnbc.com time to read: +3 min

After the U.S. Federal Reserve cut interest rates by a bumper 50 basis points , investors have been left wondering whether growth or value stocks are the best bet. On CNBC's upcoming Pro Talks , Silvia Amaro will ask value investor Sean Peche where he sees opportunities in the current market. Peche is portfolio manager at the U.K.-based Ranmore Fund Management and manages its $329 million Ranmore Global Equity Fund . As of Aug. 31, the Ranmore Global Equity Fund has returned 21.6% over the last year, underperforming its benchmark MSCI World Index's 24.4%. CNBC Pro subscribers can watch Pro Talks live on Wednesday, Sept. 25, at 7 a.m.

Persons: Silvia Amaro, Sean Peche, He'll, Warren Buffett, Eli Lilly, ager, CNBC's Silvia Amaro Organizations: U.S . Federal Reserve, Ranmore Fund Management, Global Equity Fund, Investors, Ranmore, Equity, Petrobras, Baidu, ABN Amro, Ranmore Global Equity Fund, Decillion Fund Management, Orbis Investment Advisory, CNBC, Beyond Locations: Carrefour, China, U.S, London

☆ ‘Greed, greed, greed’: Sanders demands Ozempic maker lower prices
▼ + stars: | 2024-09-24 | by ( Meg Tirrell | Tami Luhby | ) edition.cnn.com time to read: +7 min

“We are very committed to making sure that Americans have access at an affordable price point for our medicines,” Jorgensen replied. Similarly, Wegovy’s list price is $1,349 in the US, but it costs $186 in Denmark, $140 in Germany and $92 in the United Kingdom, he said. Tuesday’s hearing boiled down to a familiar argument over who is responsible for the US’s higher prices: drug companies that set starting – or “list” – prices or pharmacy benefit managers, the middlemen that negotiate discounts on those list prices in exchange for favorable insurance coverage and access. Jorgensen said Novo Nordisk pays back about 75% of its medicine sales in rebates, discounts and fees, so the net price it receives is far lower than the list price. “The broad totality is that less patients have access to our medicines when we lowered the price,” Jorgensen told Sen. Maggie Hassan, D-New Hampshire, after she pressed him to reduce list prices.

Persons: Sen, Bernie Sanders, ” Sanders, Lars Fruergaard Jorgensen, ” Jorgensen, “, Sanders, Jorgensen, it’s, Maggie Hassan, drugmakers, ”, PBMs, scot, ” Sen, Tim Kaine, Roger Marshall, Eli Lilly, Dr, Sanjay Gupta, Tammy Baldwin Organizations: CNN, Nordisk’s, US, Health, Education, Labor, Pensions, Yale, Novo Nordisk’s Ozempic, Novo Nordisk, Pharmaceutical Care Management Association, Nordisk, Novo Nordisk’s, Federal Trade Commission, CVS, Cigna’s, Republican, Wegovy’s, CNN Health, Medicare, Services Locations: United States, Danish, America, Canada, Denmark, Germany, United Kingdom, New Hampshire, Big, Virginia, Kansas, Novo, Wisconsin

☆ Modelo maker Constellation Brands jumps, and the S&P 500 eyes another record close
▼ + stars: | 2024-09-23 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. After struggling near the open, consumer staples is making a push higher on the daily S & P 500 sector leaderboard. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, There's, We're, Piper Sandler, Brown, Forman, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, ., Constellation Brands, Corona, Modelo, Sunday, Abbott Laboratories, GE Healthcare, Novo Nordisk, Apple, Microsoft, Nvidia, Broadcom, Motors, Starbucks, Thor, Philadelphia Federal, Conference, Richmond, Jim Cramer's Charitable

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices. PBMs work with insurance companies to negotiate discounted prices from drug companies in exchange for including the drugs in their coverage. The drug was priced at $274 in 2017, as a result of the PBMs rebate system strategy, the FTC said. In July, Democratic and Republican lawmakers blamed executives from Caremark, Express Scripts and Optum Rx for sky-high prescription drug prices in the U.S. during an oversight committee hearing. The lawsuit also comes as states — most recently Vermont — have sued PBMs, alleging they drive up drug costs.

Persons: Cigna, Eli Lilly, Rahul Rao, It’s, Raja Krishnamoorthi, PBMs Organizations: Federal Trade Commission, FTC, CVS, Cigna's, Zinc Health, Ascent Health, Emisar Pharma Services, UnitedHealth, CVS Health, Novo Nordisk, Democratic, Republican, Caremark, New York Times, Republicans, ” Rep Locations: U.S, FTC’s, Vermont

Search resuls for: "Lilly"

25 mentions found